Endovascular Treatment of an External Iliac Artery Dissection Causing Early Renal Graft Dysfunction

Rajesh Vijayvergiya1, Ashish Sharma2, Sarbpreet Singh2

  • 1Department of Cardiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
586
Work Done on a System by External Force01:11

Work Done on a System by External Force

The work done by an external force on a particle changes its kinetic energy. However, internal forces must also be considered for a system of interacting particles. The potential energy formulation helps formulate the effect of internal forces. The net work done by an external force can be written in terms of the total change of mechanical energy, which includes both kinetic and potential energies.
In the presence of a non-conservative opposing force, like friction, some part of the work done...
2.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
451
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
478
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
601
External and Internal Respiration01:24

External and Internal Respiration

External respiration occurs in the lungs, and it is the first step in the journey of oxygen inside the body. When we inhale, oxygen enters our lungs and diffuses across the thin alveolar membrane. The alveoli are tiny, air-filled sacs that provide a vast surface area for gas exchange. Oxygen in the alveoli has a higher partial pressure (105 mmHg) than in the adjacent pulmonary capillaries (40 mmHg), establishing a pressure gradient. As a result, oxygen molecules move from the alveoli into the...
7.4K